Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 2, 2014, Pages 481-495

  Ma, Jin ^c   Wu, Huiling ^a,c   Zhao, Cathy Y ^c   Panchapakesan, Usha ^b,c   Pollock, Carol ^b,c   Chadban, Steven J ^a,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Diabetic nephropathy; Fibrosis; Podocytes; Toll like receptor 2

Indexed keywords

AUTACOID; LIGAND; MESSENGER RNA; TLR2 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 2;

ALBUMINURIA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; MACROPHAGE; MALE; METABOLISM; MOUSE; NEPHRITIS; PATHOLOGY; PODOCYTE; SIGNAL TRANSDUCTION; TIME;

DIABETIC NEPHROPATHY; FIBROSIS; PODOCYTES; TOLL LIKE RECEPTOR 2;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; KIDNEY; LIGANDS; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEPHRITIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 2;

EID: 84894026294     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C and Parving HH. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003; 26: 1258-1264.
2. White SL, Cass A, Atkins RC and Chadban SJ. Chronic kidney disease in the general population. Adv Chronic Kidney Dis 2005; 12: 5-13.
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS and Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539.
4. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, Lovato T, Richardson M, Myers BD and Nelson RG. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 2012; 82: 1010-1017.
5. Lim AKH and Tesch GH. Inflammation in Diabetic Nephropathy. Mediators Inflamm 2012; 2012: 12.
6. Lin M, Yiu WH, Wu HJ, Chan LY, Leung JC, Au WS, Chan KW, Lai KN and Tang SC. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 86-102.
7. Medzhitov R and Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
8. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
9. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002; 111: 927-930.
10. Medzhitov R, Preston-Hurlburt P and Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397.
11. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-835.
12. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002; 23: 509-512.
13. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD and Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277: 15107-15112.
14. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ and Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26: 174-179.
15. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM and Grone HJ. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-2233.
16. Akira S and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
17. Janeway CA Jr and Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
18. Ando M, Shibuya A, Tsuchiya K, Akiba T and Nitta K. Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients. Kidney Int 2006; 70: 358-362.
19. Anders HJ, Banas B and Schlondorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15: 854-867.
20. Banas MC, Banas B, Hudkins KL, Wietecha TA, Iyoda M, Bock E, Hauser P, Pippin JW, Shankland SJ, Smith KD, Stoelcker B, Liu G, Grone HJ, Kramer BK and Alpers CE. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008; 19: 704-713.
21. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF and Chadban SJ. TLR4 activation mediates kidney ischemia/ reperfusion injury. J Clin Invest 2007; 117: 2847-2859.
22. Zhang B, Ramesh G, Uematsu S, Akira S and Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 2008; 19: 923-932.
23. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, Akira S, van der Poll T, Weening JJ and Florquin S. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115: 2894-2903.
24. Brown HJ, Lock HR, Sacks SH and Robson MG. TLR2 stimulation of intrinsic renal cells in the induction of immune-mediated glomerulonephritis. J Immunol 2006; 177: 1925-1931.
25. Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlondorff D and Anders HJ. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2006; 17: 141-149.
26. Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, Hong SC and McInerney MF. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol 2006; 18: 1101-1113.
27. Devaraj S, Tobias P, Kasinath BS, Ramsamooj R, Afify A and Jialal I. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol 2011; 31: 1796-1804.
28. Devaraj S, Tobias P and Jialal I. Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 2011; 55: 441-445.
29. Devaraj S, Jialal I, Yun JM and Bremer A. Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism 2011; 60: 256-259.
30. Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop PH and Lehto M. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes care 2009; 32: 1689-1693.
31. Nagata M and Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992; 42: 148-160.
32. McWhinnie DL, Thompson JF, Taylor HM, Chapman JR, Bolton EM, Carter NP, Wood RF and Morris PJ. Morphometric analysis of cellular infiltration assessed by monoclonal antibody labeling in sequential human renal allograft biopsies. Transplantation 1986; 42: 352-358.
33. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA and Tesch GH. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009; 52: 1669-1679.
34. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR, Saito Y and Betsholtz C. A new method for large scale isolation of kidney glomeruli from mice. Am J Path 2002; 161: 799-805.
35. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR and Chadban SJ. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010; 21: 1878-1890.
36. Mauer M and Drummond K. The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes 2002; 51: 1572-1579.
37. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108: 1583-1587.
38. Mundel P and Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13: 3005-3015.
39. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH and Stehouwer CD. Serum high-mobility group box-1 levels are positively associated with micro-and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Eur J Endocrinol 2012; 166: 325-332.
40. Miyamoto S, Shikata K, Miyasaka K, Okada S, Sasaki M, Kodera R, Hirota D, Kajitani N, Takatsuka T, Kataoka HU, Nishishita S, Sato C, Funakoshi A, Nishimori H, Uchida HA, Ogawa D and Makino H. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes 2012; 61: 897-907.
41. Nogueira-Machado JA, Volpe CM, Veloso CA and Chaves MM. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 2011; 15: 1023-1035.
42. Devaraj S, Dasu MR, Park SH and Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009; 52: 1665-1668.
43. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC and Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93: 578-583.
44. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Ogawa Y, Imamaki H, Kawanishi T, Ishii A, Koga K, Mori KP, Kato Y, Sugawara A and Nakao K. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia 2012; 55: 2256-2266.
45. Lin M, Yiu WH, Wu HJ, Chan LY, Leung JC, Au WS, Chan KW, Lai KN and Tang SC. Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy. J Am Soc Nephrol 2012; 23: 86-102.
46. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L and Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
47. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC and Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65: 116-128.
48. Ikezumi Y, Hurst LA, Masaki T, Atkins RC and Nikolic-Paterson DJ. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003; 63: 83-95.
49. Nikolic-Paterson DJ and Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 2001; 16 Suppl 5: 3-7.
50. Nguyen D, Ping F, Mu W, Hill P, Atkins RC and Chadban SJ. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006; 11: 226-231.
51. Dasu MR, Devaraj S, Park S and Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010; 33: 861-868.
52. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA and Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
53. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G and de Kleijn DP. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008; 102: 257-264.
54. Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, van der Poll T, Florquin S and Leemans JC. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol 2010; 21: 1299-1308.
55. Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA, Rink RR and Meldrum KK. Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J Surg Res 2011; 168: e61-69.